Navigation Links
Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation
Date:10/5/2011

MIAMA BEACH, FL (October 4, 2011)In a new study led by Fox Chase Cancer Center radiation oncologist Natasha Townsend, M.D., researchers have found that Gleason scores determined by pathologists at Fox Chase Cancer Center more accurately predict the risk of recurrence than Gleason scores from referring institutions. She presented the new research at the 53rd Annual Meeting of the American Society for Radiation Oncology on Monday, October 3.

When a man is diagnosed with prostate cancer, his tumor is assigned a Gleason score a number between 2 and 10 indicating the aggressiveness of the cancer and likelihood that the cancer will spread to other parts of his body. In general, Gleason scores 2 to 6 are considered low, 7 is intermediate, and 8 to 10 are high. A patients Gleason score is used to make important treatment decisions.

Townsend and her team looked at the records of 1,649 men who had undergone radiation therapy at Fox Chase between 1994 and 2007. Fox Chase pathologists reviewed the cases of every patient referred to the Center from another institution and determined the Gleason score, so Townsend compared those scores to scores from pathologists at the referring institutions (e.g. urologists, private pathologists' offices, and other centers that specialize in prostate cancer treatment).

A minor increase or decrease in Gleason score can significantly alter a patient's treatment, says Townsend. "We learned that twenty percent, or one in five men, with a Gleason score 7 by the referring institution were determined to have a Gleason score 2 to 6 at Fox Chase," Townsend added. "This is important because not only is the prognosis much better but, it changes what treatment might be recommended. For example, patients with Gleason 6 disease are more likely to be offered brachytherapy (i.e. prostate radioactive seeding) and uncommonly treated with androgen deprivation therapy, which strongly impacts quality of life."

Even greater benefits were seen in patients determined to have Gleason score 8 to10 disease by the referring institution. "An alarming 58% of patients with Gleason score 8 to 10 disease in our study were unconfirmed. These patients were found to have lower Gleason scores and similarly better prognosis," says Townsend. Patients with Gleason score 8 to 10 are universally characterized as having "high-risk" disease and a common practice standard is treatment with combination external beam radiotherapy and hormone therapy. When the Gleason score is lower, physicians are more confident omitting hormone therapy and avoiding the side effects that go along with that treatment.

Pathologists who specialize in prostate cancer likely explain the difference between the Gleason scores. "Most cases were examined by an oncologic pathologist with a special experience in urologic pathology," says Tahseen Al-Seleem, M.D., Fox Chase pathologist and co-author on the study. "Cases with discrepancy in diagnosis or grading with the outside institutions were examined by a panel of at least two oncologic pathologists until a consensus diagnosis was reached."

Changing the Gleason score is meaningless however, unless the changes better predict how patients will do following treatment. "Historically, we know Gleason score 6 patients fare better than Gleason 7, who fare better than Gleason 8 to10. Our study shows that the Fox Chase Gleason scores better predicted this pattern than the referring institutions. This reassures us that the changes made by Fox Chase pathologists were more accurate, enabling our doctors to better advise patients about treatment options and outcomes," says Mark K. Buyyounouski, M.D., M.S., Fox Chase radiation oncologist and senior author on the study. "Quality treatment for prostate cancer begins with understanding how aggressive the cancer may be and how far along it may have progressed. This study is an example of how a second opinion about the biopsy results improves quality."


'/>"/>

Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Hollywood-Style Liposuction Comes to DC: Chevy Chase Smartlipo Brings Revolutionary Laser-Assisted Liposuction to DC Metro Area
2. Torchmark Corporation Declares Dividend and Resumes Stock Repurchases
3. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
4. Grand Opening of LIFE Ionizer Australia Launches with a Free Ionizer Upgrade with Purchase of Alkaline Water Ionizer from LIFE Ionizer Australia
5. A New Twist On Convert to Purchase
6. Ensemble Healthcare Properties Purchases North Valley Medical Plaza
7. ARI Purchases Intercytex Assets
8. CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases
9. Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase
10. R-Biopharm Group Purchases a Majority Ownership in Trilogy Lab, Expanding US Operations
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology: